Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer
Ethan Brill(Center for Cancer Research), Jung‐Min Lee(National Cancer Institute)
Cited by 79
Related Papers
No related papers found
Powered by citation graph analysis